A Delaware federal judge ruled on Oct. 13 that Actavis Laboratories FL Inc. infringed three patents with a planned generic version of the weight-loss drug Contrave, rejecting the company's defense as a "classic case" of hindsight bias.
October 16, 2017 at 11:26 PM
1 minute read
A Delaware federal judge ruled on Oct. 13 that Actavis Laboratories FL Inc. infringed three patents with a planned generic version of the weight-loss drug Contrave, rejecting the company’s defense as a “classic case” of hindsight bias.
In a 35-page opinion, U.S. District Judge Richard G. Andrews of the District of Delaware said that Actavis had failed to invalidate Orexigen Therapeutics Inc.’s patents during a three-day trial in June.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
